...
首页> 外文期刊>Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners >A survey of global biosimilar implementation practice conducted by the International Society of Oncology Pharmacy Practitioners
【24h】

A survey of global biosimilar implementation practice conducted by the International Society of Oncology Pharmacy Practitioners

机译:肿瘤科学生学科国际社会进行全球生物仿生实施实践的调查

获取原文
获取原文并翻译 | 示例

摘要

Background The International Society of Oncology Pharmacy Practitioners (ISOPP) Biosimilars Task Force was charged to develop educational activities and resources to assist members when implementing biosimilar medicines into their local practice. To facilitate the process, the task force conducted a survey in order to understand biosimilar implementation practice by ISOPP members across the world and the challenges that oncology pharmacists face when adopting biosimilars into their clinical practice. Methods A cross-sectional survey was conducted between 20 April 2019 and 27 May 2019. Members of ISOPP and a number of national oncology pharmacy groups were invited to complete the survey. The survey contained 29 items and consisted of three sections: respondents’ demographics, respondents’ institutional practice relating to biosimilar implementation and post implementation practice at the respondents’ institutions. Descriptive statistics were utilized to analyze the survey results. Results A total of 265 ISOPP members were surveyed, with 50 members providing a response (response rate?=?19%). In addition, 40 nonmembers participated in the survey, bringing the total to 90 respondents. The most common factors that influence the decision to implement use of a biosimilar as reported by respondents are medication costs/pricing (92%), available clinical data (73%), and product availability (63%). Respondents also commented on the barriers to biosimilar implementation at their institutions, which included a reluctance of prescribers to use biosimilars (due to the lack of familiarity or perceived inferiority), a reluctance to switch established patients from an originator to a biosimilar and the preferences of insurance companies or funding bodies. Conclusion The results of this survey reinforce the need for greater education and training for health care professionals in the use of biosimilars, the importance of sharing good practice, and a need for standardization.
机译:背景技术国际肿瘤科学生学会(ISOPP)生物仿制生物赎罪者的工作队被收取制定教育活动和资源,以协助成员在将生物仿制药中纳入当地的实践时。为了促进该过程,工作队进行了一项调查,以了解世界各地的ISOPP成员的生物拖尾实施实践以及肿瘤药学家在采用生物仿制性进入其临床实践时面临的挑战。方法对2019年4月20日至2019年5月20日之间进行横断面调查。邀请ISOPP和一些国家肿瘤学专家组的成员完成调查。该调查载有29项,由三个部分组成:受访者的人口统计学,受访者的制度实践与BioSimilar实施以及受访者机构的职位审查做法。利用描述性统计分析调查结果。结果共有265名ISOPP成员进行调查,50名成员提供响应(响应率?=?19%)。此外,40人参加了调查,将总额达到90名受访者。影响受访者报告的实施生物素线决定的最常见因素是药物成本/定价(92%),可用的临床数据(73%)和产品可用性(63%)。受访者还评论了他们机构的生物仿制性实施的障碍,这包括不愿意使用生物纤维单体(由于缺乏熟悉或感知的自卑),这是一种不愿意将所建立的患者从发起者转换为生物仿制物和偏好保险公司或融资机构。结论该调查的结果加强了对使用生物仿制物的卫生保健专业人员的更多教育和培训,共享良好做法的重要性以及对标准化的必要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号